What was Bristol Myers Squibb's primary business focus in 1994?

Based on the general nature of a 10-K filing for a pharmaceutical company like Bristol Myers Squibb in 1994, its primary focus would have been on the development, manufacturing, and marketing of pharmaceutical products and healthcare services.

Where can I find specific financial data like revenue and profit from this filing?

The provided excerpt is a directory listing and does not contain the detailed financial statements. To find specific financial data such as revenue, profit, balance sheet, and cash flow information, you would need to access the full .txt or other document files linked within the SEC EDGAR database for this filing.

What were the major risks or challenges Bristol Myers Squibb might have faced in 1994?

While not detailed in the excerpt, typical risks for a pharmaceutical company in 1994 would include patent expirations on key drugs, clinical trial failures for new drug candidates, regulatory hurdles for drug approvals, competition from other pharmaceutical companies, and pricing pressures from healthcare providers and governments.

How did the merger of Bristol-Myers and Squibb in 1989 impact this 1994 filing?

The 1994 filing would reflect the integrated operations of the merged entity. The integration process, strategic decisions regarding the combined product portfolios, and realization of synergies from the merger would have been significant considerations and potentially discussed within the full report.

BRISTOL MYERS SQUIBB CO 10-K FY1994 Annual Report

Summary

Bristol Myers Squibb's 1994 10-K filing provides a snapshot of the company's financial health and strategic direction as of December 30, 1994. While specific financial performance figures and detailed segment breakdowns are not provided in the excerpt, the filing indicates a company actively engaged in its core pharmaceutical and healthcare businesses. Investors would look to this report for insights into the company's product portfolio, research and development pipeline, and any significant corporate developments or risks that may have impacted the business during the reporting period. Given the era, key considerations for investors likely revolved around the success of existing blockbuster drugs, the progression of new drug candidates through clinical trials, and the competitive landscape within the pharmaceutical industry. The company's ability to navigate regulatory environments and manage its global operations would also be critical factors influencing its stock performance. This filing serves as a foundational document for understanding the company's position and outlook at that time.

Key Highlights

1The 10-K filing covers the fiscal year ending December 30, 1994, for Bristol Myers Squibb Co. (BMY).
2The filing was officially submitted to the SEC on March 28, 1995.
3This report provides essential regulatory disclosure for the period, offering a look into the company's operations and financial standing.
4Investors can analyze this report to understand the company's performance and strategic initiatives during 1994.
5Key areas of interest for investors would typically include product revenues, research and development investments, and market strategies.
6The filing is a primary source for assessing the company's business segments and any material risks or opportunities identified.
7It serves as a critical document for historical financial analysis and understanding the company's trajectory in the mid-1990s.

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 1994

Summary

Key Highlights

Frequently Asked Questions